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Abstract
Postgonadectomy adrenocortical tumorigenesis is a strain-specific phenomenon in inbred mice,
assumed to be caused by elevated LH secretion and subsequent ectopic LH receptor (LHR)
overexpression in adrenal gland. However, the molecular mechanisms of this cascade of events
remain unknown. In this study, we took advantage of the mouse strain dependency of the phenotype
to unravel its genetic basis. Our results present the first genome-wide screening related to this
pathology in two independent F2 and backcross populations generated between the neoplastic DBA/
2J and the nonsusceptible C57BL/6J strains. Surprisingly, the postgonadectomy elevation of serum
LH was followed by similar up-regulation of adrenal LHR expression in both parental strains and
their crosses, irrespective of their tumor status, indicating that it is not the immediate cause of the
tumorigenesis. Linkage analysis revealed one major significant locus for the tumorigenesis on
chromosome 8, modulated by epistasis with another quantitative trait locus on chromosome 18.
Weight gain, a secondary phenotype after gonadectomy, showed a significant but separate
quantitative trait locus on chromosome 7. Altogether, postgonadectomy adrenocortical
tumorigenesis in DBA/2J mice is a dominant trait that is not a direct consequence of adrenal LHR
expression but is driven by a complex genetic architecture. Analysis of candidate genes in the
tumorigenesis linkage region showed that Sfrp1 (secreted frizzled-related protein 1), a tumor
suppressor gene, is differentially expressed in the neoplastic areas. These findings may have
relevance to the human pathogenesis of macronodular adrenal hyperplasia and adrenocortical tumors
in postmenopausal women and why some of them develop obesity.
The molecular pathogenesis of adrenal tumors is poorly understood (1), as exemplified by
human adrenal incidentalomas, which are a common opportune finding (2). Interestingly,
adrenal gland neoplasms often develop after gonadal failure and chronic gonadotropin
elevation, as in postmenopausal women (3,4) or in men with acquired primary hypogonadism
(5). The connection between the gonadal and adrenal pathologies remains elusive, but
conspicuously, a subset of the adrenal tumors are gonadotropin responsive (6,7). Likewise, in
ACTH-independent Cushing's syndromes, the adrenals of some patients have been reported to
be gonadotropin responsive (8). Moreover, rare cases of pregnancy-associated Cushing's
syndrome with adrenal hyperfunction related to elevated human chorionic gonadotropin levels
have been described (9). Another clinical syndrome of relevance is the macronodular adrenal
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hyperplasia, where ectopic G protein-coupled receptor expression, e.g. of the LH receptor
(LHR), is a pathognomonic finding (8).
The connection between high gonadotropin levels and adrenocortical pathologies is clearer in
some mammalian models. For example, neutered ferrets develop with high frequency the
syndrome of gonadotropin-induced adrenocortical neoplasia with associated Cushingoid
obesity (10). Studies on genetically modified mice have revealed that the etiology of these
pathologies is due to a combination of genetic and hormonal factors (11-13). Excessive LH
levels, induced by ovariectomy (Ovx) or transgenic LH overexpression, lead to ectopic LHR
overexpression in the adrenal gland, followed by adrenocortical hyperplasia or tumorigenesis
(14,15). However, the exact molecular mechanisms leading to this apparent gonadotropin-
dependent adrenocortical neoplasia remain unknown.
In addition, the postgonadectomy tumorigenesis in mice occurs only in specific inbred strains,
indicating a clear genetic component in this response. It is well recognized that only certain
mouse strains (e.g. DBA/2J and CE/J) develop adrenocortical neoplasms in response to
prepubertal Ovx with high penetrance, whereas other nonsusceptible strains (e.g. C57BL/6J
and FVB/N) never develop them (16,17). Organ transplantation experiments have established
that the adrenal glands of susceptible strains exhibit an inherent predisposition for tumor
formation in response to the hormonal changes after Ovx, but the genetic basis of this
susceptibility is unknown.
After Ovx, DBA/2J females exhibit high serum LH levels, with subsequent development of
adrenocortical tumors that overexpress LHR and the transcription factor GATA-4 (14). The
adrenocortical neoplasms originate by proliferation of small spindle-shaped cells (termed A
cells) in the subcapsular region (16). More advanced neoplasia is defined by nests of round
steroidogenic lipid-laden cells, termed B cells, among the A cells (18). Interestingly, along
with tumorigenesis, DBA2/J mice also develop obesity, reminiscent of Cushing's syndrome of
postmenopausal women.
We hypothesized that the high penetrance and strict strain dependence of the gonadectomy-
induced adrenal tumors provide the basis for a genetic approach to identify the genomic regions
related to, and genes responsible for, the pathogenesis.
In the present study, we describe the first genetic approach to explore the molecular
pathogenesis of postgonadectomy (or gonadotropin-induced) adrenal gland tumorigenesis and
obesity in two selected strains of mice by performing a genome-wide screen in segregating
populations derived from the nonsusceptible C57BL/6J and the susceptible DBA/2J strains.
We report that epistasis between quantitative trait loci (QTL) is an important contributor to the
genetics of mouse adrenocortical tumorigenesis and that this pathology could be regarded as
a complex genetic trait. Sfrp1 (secreted frizzled-related protein 1), a tumor suppressor gene, is
a positional candidate gene that could be proposed as one of the biological candidate genes in
the induction of the adrenal tumors.
Materials and Methods
Experimental animals and treatments
All animal work was carried out in accordance to the United Kingdom Home Office Project
License and the personal licenses held by the authors. Mice of inbred strains DBA/2J and
C57BL/6J were purchased from Charles River Laboratories UK (Kent, UK), and all mice were
kept in specific pathogen-free conditions in controlled conditions of light and temperature and
fed with standard laboratory animal food and water ad libitum.
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Fifty F1 progeny were generated by crossing DBA/2J with C57BL/6J, and intercrosses between
F1 animals produced 208 F2 females for the linkage study. Twenty-five F1 females were also
backcrossed with C57BL/6J males to generate 125 backcross (BC) females used for the linkage.
Prepubertal Ovx was performed at 21–24 d of age. Isoflurane inhalation anesthesia was used
during surgical procedures, and buprenorphine was used as postoperative analgesia. All mice
produced (including F2 and BC mice), had postgonadectomy WG monitored every month up
to the time of termination, and the final WG at 6 months upon Ovx was taken for the linkage
study. The same F2 and BC mice were assessed for their adrenal tumor status (TS) as described
in Adrenocortical tumor assessment below. At specified times after surgery (up to 6 months
for the linkage studies), mice were killed by CO2 inhalation. Blood samples were obtained at
the time of death. At autopsy, several tissues including liver and adrenals were dissected out
and snap-frozen in liquid nitrogen or fixed in neutral formalin solution overnight before
embedding in paraffin and sectioned (6 μm) for staining with hematoxylin-eosin or for
immunohistochemistry experiments. Some harvested adrenals were also used to isolate total
RNA using the RNeasy Mini Kit (QIAGEN Inc., Valencia, CA), according to the
manufacturer's instructions.
Hormone measurements
Serum LH concentrations were measured using an immunofluorometric assay (Delfia, Wallac
Oy, Turku, Finland) as described previously (19). Corticosterone concentrations were
measured using an RIA (MP Biomedicals, LLC, Orangeburg, NY; ref. 07-120102). Prolactin
concentrations were measured by RIA as described earlier (20). Estradiol concentrations were
measured using fluoroimmunoassay (Delfia). All hormonal assays were performed from each
of the animal groups, as mentioned in the Results (n = 8–13 animals per group), 6 months after
Ovx.
Adrenocortical tumor assessment
Because the affected animals show bilateral neoplasias, only monolateral evaluation of the
tumors was performed. After killing, the adrenal glands were dissected out and fixed in formalin
overnight. Tissues were dehydrated in ethanol and left in Histoclear buffer overnight. Adrenals
were paraffin embedded, sectioned at 6 μm thickness, and then stained with hematoxylin-eosin
according to standard protocols. Eight to 10 slides of five sections were generated for each
gland and screened for complete evaluation. The adrenal TS was confirmed when concomitant
presence of B cells within foci of A cell expansions were found to disturb the normal
architecture of the cortex.
Alternatively, for linkage study, TS was staged. Stage 1 indicated a normal gland as it appears
in non-Ovx CTL. Stage 2 designated presence of subcapsular foci of cell proliferation with no
abnormal proliferation yet. Glands classified within stages 1 and 2 were considered as
nontumorous. Stage 3 showed B cells associated with A cell expansion in the inner part of the
cortex. Stage 4 indicated well-established tumor with total cortical disorganization. Glands
classified within stages 3 and 4 were considered as tumorigenic.
Inheritance of the traits
Weight gain (WG) was followed up to 6 months after Ovx in F1 (n = 46), DBA/2J (n = 25),
C57BL/6J (n = 24), and non-Ovx animals (n = 10–14). TS was assessed at 6 months after Ovx
in the same groups (except n = 20 in Ovx-F1).
Bernichtein et al. Page 3
Endocrinology. Author manuscript; available in PMC 2008 October 1.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Immunohistochemistry
Paraffin-embedded tissue sections were deparaffinized, hydrated, and boiled in 10 mM citric
acid (pH 6.0) for antigen retrieval. Three percent H2O2 in PBS was used to block endogenous
peroxidases, after which the slides were incubated with 1.5% normal serum in PBS. Sections
were stained with primary polyclonal goat antimouse LHR M-17 antibody or primary
polyclonal goat antihuman FRP-1 C-19 antibody (sc-26434 and sc-7425, respectively; Santa
Cruz Biotechnology, Santa Cruz, CA) at dilution 1:100 for 1 h at room temperature. The
avidinbiotin immunoperoxidase system was used to visualize bound antibody (Vectastain Elite
ABC kit; Vector Laboratories, Burlingame, CA) with diaminobenzidine substrate kit
(SK-4100; Vector). Slides were then counterstained with hematoxylin.
Laser capture microdissection of adrenal cortex
Adrenal glands were embedded in Tissue-Tek (Miles, Elkhart, IN) and frozen in liquid
nitrogen. Cryosections (10 μm thick) were cut and mounted onto ribonuclease-treated
membrane slides (PALM Microlaser Technologies AG, Bernried, Germany). Sections were
fixed (3 min) in 65% ethanol, counterstained briefly (5–10 sec) with hematoxylin-eosin, and
dehydrated in 100% ethanol. Neoplastic area and normal adjacent cortex area were isolated
from these sections using the PALM Robot-Microbeam version 4.0 (PALM Microlaser
Technologies). Laser capture was performed with an approximately 15- to 30-μm laser beam,
a laser power of 50 mV, and a laser power duration of 4–6 msec. Cells were collected in PALM
AdhesiveCaps tubes that were stored on dry ice until RNA extraction. RNA was extracted
within 2 h of cell collection using the RNeasy Micro Kit (QIAGEN), according to the
manufacturer's instructions. All RNA extracted was used for the RT reaction (Invitrogen Life
Technologies, Inc., Paisley, UK) as described below.
RT-PCR
One microgram of total RNA was reverse-transcribed using the SuperScript First-Strand
Synthesis System for RT-PCR (Invitrogen Ltd., Paisley, UK), according to the manufacturer's
instructions. The resulting first-strand cDNA was used as a template in subsequent PCR. Sense
and antisense primers for LHR and L19 ribosomal protein internal control were designed as
previously described (15). PCR conditions for LHR were as follow: 94 C for 1 min, 53 C for
1 min, and 72 C for 1 min for 29 cycles. Same PCR conditions were used for L19 except 27
cycles and annealing temperature of 60 C. The sense primer for Sfrp1 was 5′-
TGCTCAAATGTGACAAGTTC-3′, and the antisense primer was 5′-
CGTGGTTTTTCATTCTCTTC-3′. PCR conditions for Sfrp1 were 94 C for 1 min, 47 C for 1
min, and 72 C for 1 min for 30 cycles.
Then, PCR products were loaded on 2% agarose gel containing ethidium bromide to identify
the amplicons. Densitometric analysis was performed with the Image J software (Image J
1.36b; Wayne Rasband, National Institutes of Health, Bethesda, MD), and gene expression
was normalized to L19 expression. Results for LHR are expressed as fold induction vs. the
background signal measured in non-Ovx control samples, and results for Sfrp1 are expressed
as percentage of expression vs. expression in normal tissue.
Statistical analysis
The data presented are expressed as mean ± SD, with the minimum number of samples being
five per group. Statistically significant differences were determined by nonparametric t test
(Mann Whitney U test) or by χ2 goodness-of-fit test (with one degree of freedom; critical value
= 3.8); P < 0.05 was considered statistically significant.
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Genome-wide scan
Genomic DNA was isolated from liver tissue, purified, and quantified according to standard
protocols.
Using the Mouse Phenome Database (http://www.jax.org/phenome/snp.html) and the NCBI
Database (build 36.1), 192 informative single-nucleotide polymorphisms (SNPs) that
distinguish the two parental strains (i.e. DBA/2J and C57BL/6J) were selected at about 10-cM
intervals across the mouse genome, and not more than 5 cM from the chromosome ends. The
average spacing between SNPs was 7.7 cM (± 4.5 cM), the largest gap between two SNPs
being 20 cM.
SNP assays were performed using the SEQUENOM MassARRAY system. Briefly, primers
for PCR and single-base extension were designed by using the MassARRAY Assay Design
3.1 software package (SEQUENOM, Hamburg, Germany), and SNPs were multiplexed into
a maximum of 36-plex pools by using the software. SNP amplification and iPLEX reaction
were carried out according to the iPLEX Gold application guide. Completed genotyping
reactions were spotted in nanoliter volumes onto a matrix arrayed into 384 elements on a silicon
chip (SEQUENOM SpectroCHIP), and the allele-specific mass of the extension product was
determined by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry.
Analysis of data by MassARRAY Typer 3.4 software for iPLEX generates automated allele
calling. Plates were considered successful if more than 75% of genotypes could be called and
there was no significant deviation from Hardy-Weinberg equilibrium (P > 0.05).
Linkage analysis
The genetic map in both F2 and BC crosses was estimated from the data using the Lander-
Green algorithm (21), and genotyping errors were identified by calculating the error LOD for
each genotype as described by Lincoln and Lander (22).
We carried out genome-wide linkage analysis to identify genomic regions associated with TS
and WG using the R/qtl package (23) in the F2 (n = 208) and BC (n = 125) populations. We
used a two-step approach by first identifying the regions of interest showing nominal evidence
for linkage (two-point LOD scores > 3) and then refining the QTL mapping by adding
additional SNPs. LOD scores were computed at 1-cM intervals, and empirical genome-wide
significance was calculated by 10,000 permutations (24).
Two regions were followed up in the second stage: on chromosome 7 and chromosome 8
(average marker density, two per Mbp) for WG and TS, respectively. The 1-LOD drop interval
was used as an estimate for the 90% confidence interval of the QTL (25) and was defined after
additional SNPs had been added in the region to obtain the highest information content. For
the genome-scans of both TS (staged from 1–4) and WG, a nonparametric model was used,
which is an extension of the Kruskal-Wallis test (23), allowing robust mapping of QTL without
concern about the precise distribution of the trait (26).
For the binary TS (affected/nonaffected), we implemented the binary model (27) using the
Haley-Knott regression method (28). To evaluate the effect of obesity, we reanalyzed the
tumorigenesis trait fitting two separate models using WG as a covariate (model 1) and using
WG as a covariate interacting with QTL genotype (model 2) (29). The difference in LOD scores
between the standard model and either model 1 or model 2 was calculated and used to estimate
the magnitude of QTL × obesity interaction. A difference of at least 1 LOD between models
was considered indicative of the QTL being affected by the obesity covariate.
Bernichtein et al. Page 5
Endocrinology. Author manuscript; available in PMC 2008 October 1.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Two-dimensional genome scan with a two-QTL model was carried out using the R/qtl package
(23) and the binary model for TS was implemented; empirical significance of the joint LOD
score was assessed by 1000 permutations.
Identical by descent (IBD) analysis
Predicted IBD blocks of shared ancestry for chromosome 8 were estimated between C57BL/
6J and DBA/2J using the Scripps Florida Mouse Database, 20k dataset (30). Block positions
were based on raw SNPs.
Results
Adrenal gland tumor development
In a preliminary experiment, prepubertal Ovx induced adrenocortical neoplasms in DBA/2J
mice (n = 13; Fig. 1A) at 6 months after surgery, with 100% penetrance, as reported before
(16). Nonsusceptible C57BL/6J mice (n = 11) never developed tumors after Ovx and retained
the normal zonal cortical organization (Fig. 1B). In an advanced tumor, spindle-shaped A cells
extended from zona glomerulosa to zona fasciculata, whereas lipid-laden B cells were clearly
visible between the tracts of A cells (Fig. 1C). As a result, a clear tumorigenic pattern was
observed in these glands with complete zonal disorganization of the adrenal cortex. The
histological appearance of tumors was similar in F1 (n = 20; Fig. 1C), BC (data not shown),
and F2 animals (Fig. 1D), suggesting the same tumorigenic event in all crosses.
Hormonal changes and adrenal LHR expression in Ovx animals
In keeping with a previous report (14), we observed a gonadectomy-induced increase in serum
LH levels (20- to 27-fold) that was similar in both parental strains when compared with non-
Ovx controls (n = 11–13 per group; Fig. 2A, inset). Similar patterns of LH levels were observed
in the F2 cross and BC mice (n = 8–13 per group; Fig. 2A), but the increases were not correlated
with WG or TS (P > 0.1).
Because the DBA/2J mice also developed massive obesity paralleling tumor growth, serum
corticosterone concentrations were assessed in the same animal groups. Gonadectomy did not
affect corticosterone levels in either the parental strains or crosses (Fig. 2B), and corticosterone
levels were not correlated with either WG or TS (P > 0.1). No tumor- or Ovx-related changes
in serum estrogen or prolactin levels were observed (data not shown).
RT-PCR analysis on adrenal gland extracts of gonadectomized mice showed clear LHR mRNA
expression and a clear increase in expression from 3 months after the surgery was observed in
F1, DBA/2J, and in nonsusceptible C57BL/6J strains (n = 3–5 per group; Fig. 3A), compared
with non-Ovx animals where the LHR gene cannot be detected. Expression after 6 months was
similar in all animals including the F2 population (Fig. 3A).
LHR expression was confirmed by immunohistochemistry (Fig. 3B). The wild-type adrenals
were immunonegative, whereas clear staining was observed within the tumors (Fig. 3B, Ovx-
F1). The cortical region also displayed clear staining in Ovx-C57BL/6J mice, indicating that
nontumorigenic adrenal glands also express LHR ectopically after gonadectomy (Fig. 3B).
Altogether, these results confirm that LHR expression is undetectable in the normal adult
adrenal gland, whereas it becomes ectopically expressed and is clearly up-regulated after Ovx.
Inheritance and segregation of the tumorigenic and obesity traits
All Ovx-F1 mice displayed significant WG from 2 months after surgery, suggesting a dominant
mode of inheritance for this trait (n = 10–46; Fig. 4). Similarly, all Ovx-F1 mice developed
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adrenocortical tumor (as shown in Fig. 1C; n = 20), which is suggestive of a dominant mode
of inheritance also for TS.
Staging of the tumors (see Materials and Methods) revealed that 70.1% of F2 and 56.8% of
BC adrenal glands were tumorigenic (Fig. 5A). These ratios were not different from those
expected in the case of a monogenic inheritance (χ2 = 0.14; P > 0.05), suggestive of genetic
control by a single gene.
The estimated heritability for WG was 58%, indicating a substantial genetic component
segregating in the F2 population for this trait. We did not observe a significant difference (P
= 0.8) in the distribution of WG for the F2 and BC populations at month 6 (17.8 ± 5 g in F2
and 17.6 ± 4 g in BC; mean ± SD; Fig. 5B), and the Castle-Wright estimation (31) indicated a
minimum of two segregating genes, suggestive of a polygenic control of WG. Although WG
coincides with adrenal tumorigenesis in DBA/2J, we did not observe a significant correlation
(P > 0.5) between WG and TS in either F2 or BC mice (Fig. 5C).
Although both WG and TS were gonadectomy induced, we concluded that TS is under a
different genetic control than WG, and accordingly, we analyzed these traits separately.
Linkage analysis
We detected significant linkage for WG on chromosome 7 (Fig. 6A), with a LOD score of 4.79
(P = 0.01) in the F2 population. Interval mapping indicated a broad region spanning about 30
cM, between SNPs rs13479333 and rs4226783 (Fig. 6B). No nominal evidence for linkage at
this locus (LOD < 1) was observed in the BC population. Other suggestive linkages in the F2
were observed on chromosomes 11 (LOD = 2.84), 1 (LOD = 2.65), 5 (LOD = 2.2), 14 (LOD
= 2.17), and 3 (LOD = 2.14).
Using a nonparametric model for staged TS in the F2 cross, we found only one highly
significant linkage, with a LOD of 5.57 (P = 0.001) for tumorigenesis (Fig. 6C). Interval
mapping indicated a broad peak spanning about 35 cM on chromosome 8, with a 1-LOD drop
from the maximum peak height defining an interval of about 10 cM located between markers
rs32607714 and rs6382288 (Fig. 6D). One other suggestive linkage was observed on
chromosome 10 (LOD = 2.2), but did not reach significance. No significant linkages were
detected in the BC population for TS, although the highest LOD (1.5) was observed at the same
locus (data not shown).
When TS was analyzed as a dichotomous trait (tumor/normal), the same QTL on chromosome
8 (LOD = 4.0; P = 0.05) was observed. Models with WG as a covariate and as a covariate
interacting with the QTL on chromosome 8 (see Materials and Methods) did not show a
significant change in the LOD score for TS (maximum change in LOD score < 0.2 in both
models), suggesting a lack of interaction between the TS locus and WG.
Two-dimensional genome scan for TS
Analysis of the segregating alleles within the TS QTL at SNP rs33209429 (peak of linkage)
revealed that 27.9% of the tumorigenic F2 animals were homozygous for the nonsusceptible
C57BL/6J allele, and 40% of the nonaffected F2 animals were homozygous for the susceptible
DBA/2J allele.
Although the TS segregation pattern in the F2 was consistent with a dominant, monogenic
model of inheritance, the underlying genetic architecture appeared to be more complex and
likely to involve a polygenic component. Therefore, we carried out a two-dimensional genome
scan for TS and tested for genome-wide QTL-QTL interaction. The only significant interaction
was obtained for two loci on chromosomes 8 and 18 (joint LOD = 8.32; P < 0.05, Fig. 7 and
Bernichtein et al. Page 7
Endocrinology. Author manuscript; available in PMC 2008 October 1.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Table 1). Although the locus on chromosome 18 did not show significant linkage in the single-
locus genome scan, it appeared to contribute to TS under a two-locus model of epistasis. This
suggests that the main susceptibility locus on chromosome 8 is likely to be modulated by a
secondary QTL on chromosome 18. We investigated the QTL region on chromosome 18
(spanning 10 Mbp between positions 80 and 90 Mbp), which includes 62 annotated genes, but
did not find any genes with obvious functional relevance to tumorigenesis.
Identification of candidate genes for TS
The TS QTL on chromosome 8 spanning a 10-cM interval contains 123 genes (according to
the NCBI genome viewer, build 36.1). Among those, 34 unknown/similar/hypothetical genes
and 42 belonging to the defensin-related cluster of genes were not prioritized as candidates for
TS.
Using IBD analysis, we excluded blocks of shared ancestry between both parental strains (see
supplemental data, published on The Endocrine Society's Journals Online web site at
http://endo.endojournals.org) and further refined the number of potential candidates to 34.
Thirty-one genes have human orthologs (Table 2), with their functions being related to
transport, transcription, proteolysis, cell cycle, metabolism, cell adhesion, and negative
regulation of the Wnt signaling pathway.
We focused on the nine genes that showed sequence variation in the coding region between
the parental strains, according to the Mouse Phenome Database and the NCBI database. Among
these genes, none have previously been reported to be expressed in the mouse adrenal gland
(databases: Unigene-ensembl, NCBI). Furthermore, we confirmed the absence of mRNA
expression in the adrenal gland for all but one of the candidate genes in the list, including Dkk4,
Zmat4, Slc20a2, Adam9, Adam18, Tpte, Mcph1, and Defensin-β1 (data not shown). On the
other hand, we could detect Sfrp1 (secreted frizzled-related protein 1) mRNA expression in
adrenal gland extracts. As shown in Fig. 8A, Sfrp1 transcripts were found in normal and
tumorigenic adrenal samples from whole glands and enriched tumorigenic areas (isolated by
laser capture microdissection), respectively (Fig. 8A), which prompted us to examine further
this gene.
The Sfrp1 tumor suppressor gene is an attractive positional candidate because it is involved in
the Wnt pathway, which has previously been suggested in adrenocortical tumorigenesis in mice
(13). We sequenced all the nonsynonymous coding variants reported between the two parental
strains for Sfrp1, as well as for each of the candidate genes where such variants have been
reported, but we could not find any evidence for associations with the TS phenotype (data not
shown). The putative promoter region of Sfrp1 was also screened for possible variants between
the two parental strains, but no SNPs were found. Alternatively, Sfrp1 expression in the
adrenocortical tumors was assessed by immunohistochemistry, and we showed that the
neoplastic regions exhibited less intense staining for the protein compared with adjacent normal
cortex (Fig. 8B, a–c). In particular, Sfrp1 staining was absent in the neoplastic A cells (Fig.
8B, d), suggesting that the absence or lower level of expression of this tumor suppressor gene
product could contribute to the initiation of tumor development. In early stages of TS (third
month after Ovx, Fig. 8B, e), characterized by A cell proliferation and zonal invasion, Sfrp1
protein was not detected in A cells compared with the adjacent normal cortex. Normal adrenal
cortex from nontumorigenic glands of Ovx-C57BL/6J mice showed regular Sfrp1 staining (Fig.
8B, f).
Discussion
We report here the first study on the genetic basis of LH-induced adrenocortical neoplasia in
nonsusceptible C57BL/6J and susceptible DBA/2J inbred strains of mice. These strains
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represent a unique physiological model that may have relevance for the pathogenesis of
postmenopausal adrenal tumors in humans. Women are exposed to high levels of LH for years
after menopause, and LH-stimulated adrenal function is a plausible hypothesis for the increased
occurrence of postmenopausal adrenal tumors and obesity. Moreover, aberrant LHR
expression has been reported in patients developing macronodular adrenal hyperplasia
associated with Cushing's syndrome (8).
Several studies on different mouse models developed by us and others have shown that there
are more than one tumor type that are induced by high LH in mouse adrenal glands (10), with
some arising from different zones of the gland such as the X zone (32) or the subcapsular
cortical zone. Interestingly, the adrenocortical tumors presented in the postgonadectomy mouse
model resemble closer luteal cell rests rather than adrenal tumors, as suggested in early work
of Fekete et al. (16). This is in accordance with our observation that these tumors do not secrete
corticosterone (Fig. 2B) and show clear expression of steroidogenic differentiation markers
and GATA-4 in the tumorigenic cortex, as reported in several studies (13-15).
Recent reports emphasize that inappropriate adrenocortical expression of nonmutated G
protein-coupled receptors, such as LHR or gastric inhibitory peptide receptor, is sufficient to
induce tumor formation (33,34). However, our data show that the ectopic LHR expression in
the adrenal cortex is not a sufficient causative event for neoplasia because also the
nonsusceptible C57BL/6J mice expressed LHR in the adrenal gland after Ovx, without
development of tumors (Fig. 3). Moreover, the switch from the predominantly adrenal
expression of transcription factor GATA-6 to expression of the gonad-specific GATA-4 has
been reported in a subset of human and mouse adrenocortical tumors (14,35), which can
amplify the adrenal overexpression of LHR (15). We detected GATA-4 mRNA in normal
adrenals of Ovx mice (data not shown), suggesting that unknown factor(s) other than LH/LHR/
GATA-4 might be involved in the etiology of the tumor phenotype.
Genetic predisposition to tumorigenesis in the adrenal gland has been inferred (36), and high
LH levels have been proposed as the trigger, to induce ectopic LHR expression in adrenal
glands (14). Although LH rise is the prerequisite for the induction of tumorigenesis in DBA/
2J animals, we showed that the TS is not the obligate consequence of high LH and adrenal
LHR overexpression (Figs. 2 and 3) because nontumorigenic Ovx-C57BL/6J animals exhibit
similar LH levels and LHR overexpression. This finding suggests that different genetic
backgrounds influencing the downstream events from LHR activation contribute to the
induction of the neoplastic phenotype. We therefore carried out a genome-wide search to
identify genetic factors associated with post-gonadectomy adrenocortical tumors in mice.
Linkage analysis identified a major locus on chromosome 8 in F2, although we did not observe
significance in the BC population. This lack of replication may be due to the lower power of
QTL detection by linkage in the BC compared with the F2 population (31). No evidence for
linkage to LHR (chromosome 17) and GATA-4 (chromosome 14) genes was found, excluding
them as candidates for tumorigenesis. We propose this locus on chromosome 8 as a new locus
involved in mouse adrenocortical tumorigenesis. One study exists on mapping mouse
adrenocortical dysplasia to the central region of chromosome 8 (37,38), at a close but distinct
genomic region. This is of potential interest because cortical cells of the affected adrenocortical
dysplasia mice contained lipid droplets characteristic of steroidogenic cells, which resembles
those of B cells in our phenotype. Interestingly, allelic imbalance of human chromosome 8p
(syntenic region to our locus) has been described in many human cancers (39), supporting the
hypothesis that genes in this region play an important role in human tumorigenesis, but none
have been reported for mouse adrenal tumors.
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A separate QTL linked to WG was identified on chromosome 7, suggesting that
postgonadectomy obesity and adrenal tumorigenesis are segregating independently. This is in
accordance with the unchanged corticosterone levels we measured in the animals after Ovx
(Fig. 2B), suggesting other genetic factors contributing to WG in this model. In accordance,
previous studies have identified several QTL for obesity on mouse chromosome 7 in several
mouse models (40-42), providing strong evidence that the WG in our model is an independent
obese phenotype from the adrenal condition.
We identified a highly significant susceptibility locus for adrenal gland tumorigenesis in DBA/
2J mice on chromosome 8. Unexpectedly, we found a significant proportion of unaffected F2
animals carrying the susceptible DBA/2J alleles at this locus. This inverse association of the
risk allele with the phenotype has been reported in humans (flip-flop phenomenon) (43) and
is usually attributable to hidden genetic heterogeneity due to sampling effects. It was
hypothesized that flip-flop associations may be attributable to undetected multilocus effects or
to noncausal variant in linkage disequilibrium with the genuine causal variant (43). Although
the observed negative association could indicate the presence of a protective allele at the locus
of interest, we hypothesized the presence of a polygenic component interacting with the major
QTL for TS.
We therefore carried out a genome-wide epistasis analysis and showed that the major QTL for
TS is significantly modulated by at least one other locus, on chromosome 18. When the
combined effect of the genotypes at both chromosome 8 and 18 loci was investigated, we
observed the resistant C57BL/6J allele in about 20% of tumorigenic F2 animals, suggesting
the presence of undetected loci of small effect. Epistasis analysis showed that 10 of 12
nonsignificant interactions (Table 1) involved the locus on chromosome 8, supporting the
hypothesis of multiple interacting loci contributing to the phenotype.
The major QTL identified on chromosome 8 spans an approximately 10-cM region, containing
31 candidate genes, orthologs to human, none of them previously identified to interact with
LHR function. Among these genes, Sfrp1 is an attractive positional candidate because it is a
dominant-negative inhibitor of the Wnt signaling pathway (44), which contributes to
tumorigenesis when dysregulated (45).
Sfrp1 is down-regulated by epigenetic modifications in several types of cancers, indicating a
putative tumor suppressor role for this gene (46,47). We have not excluded epigenesis as a
mode of action of this gene in our model, because we screened only the coding region, but to
our knowledge, no data have been reported that support epigenetic changes of Sfrp1 in a
tumorigenic mouse model. Bielinska et al. (13) reported in adrenal gland tumors from NU/J
mice a possible role for the Wnt signaling pathway in the pathogenesis, which prompted us to
test for Sfrp1 expression in our model. We found that normal adrenal glands do express
Sfrp1, as shown in C57BL/6J, whereas the expression is strongly altered in adrenocortical
tumors. Thus, subcapsular A cells, i.e. the first stage of adrenal tumors, do not seem to express
this gene, whereas cortical B cells do.
This observation may be of significance because it was recently suggested that adrenocortical
tumors from Ovx-CE/J mice are derivatives from cells of the proposed subcapsular stem cell
zone (48). In addition, there is evidence for a pool of stem or progenitor cells that reside in this
subcapsular cellular compartment, likely to play a key role in adrenal physiology as the origin
of all adrenocortical cells that migrate centripetally upon differentiation (49,50). These
adrenocortical stem cells remain pluripotent and can adopt a gonadal fate, as a reminiscence
of the adrenogonadal primordium during embryonic development. Then, when gonadotropin
levels are disproportionately high, as after Ovx, the stem cells could give rise to tumors that
resemble functional gonadal cells, as observed in adrenocortical tumorigenesis. It is not known
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whether A cells are the stem cells, but because they both originate from the same zone, the
tumorigenesis observed could be an example of stem cell metaplasia. It was recently shown
that a subset of subcapsular adrenocortical cells retain the developmental plasticity to respond
to pituitary gonadotropic stimuli and that these cells become dysregulated due to convergent
Ovx and chronic LH exposure, thus leading to hyperproliferative clusters of cells in the adrenal
cortex culminating in tumorigenesis (51).
It is noticeable that although Sfrp1 is an attractive candidate within the locus on chromosome
8, based on location, biology, and protein expression, we cannot exclude any of the other genes
within this interval. Although we did not detect gene expression for the other candidate genes,
such as Dkk4 (which is also involved in the Wnt signaling pathway), it is possible that these
genes are expressed at very low or undetectable levels. It is also possible that the genes of
interest reside in the region of IBD and had a recent mutation in one of the parental strains.
Finally, we cannot rule out that other undetected epistatic loci of small contribution, involving
other unknown candidate genes, are implicated in the regulation of the phenotype, which brings
another level of complexity to the disease. However, Sfrp1 remains a potential candidate
according to its differential expression within the adrenal gland tumor.
In conclusion, this is the first genetic study on LH-induced adrenocortical tumorigenesis in
inbred mice. We identified a major, obesity-independent QTL for TS on chromosome 8, which
is modulated via epistasis by another QTL on chromosome 18, revealing a complex genetic
architecture. We propose adrenal tumorigenesis in DBA/2J mice as a model of adrenal stem
cell dysregulation, relayed by Wnt signaling (52). We identified the Sfrp1 tumor suppressor
underlying the major QTL for TS as an attractive candidate for adrenal tumorigenesis, although
more studies are needed to confirm its role in the pathogenesis of the disease as well as to find
other associated genes.
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Fig. 1.
Adrenocortical tumor development. A, Adrenal cortex of a prepubertally Ovx-DBA/2J female,
6 months after surgery; B, adrenal gland of an Ovx-C57BL/6J mouse (6 months after surgery)
showing normal morphology and normal zonal organization of the cortex, with distinct zona
glomerulosa (zg), zona fasciculata (zf), and X zone (x); C and D, tumors from F1 and F2 mice,
respectively, showing complete disruption of the zonal organization due to neoplasia.
Accumulation of spindle-shaped A cells (arrows) and lipid-laden B cells (arrowheads) is
clearly visible in the cortex as a feature of tumorigenesis. Objective magnification is indicated
at the bottom right corner of each panel.
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Fig. 2.
Hormone concentrations 6 months after prepubertal Ovx in F2 and BC animals. A, Serum LH.
As shown in both parental strains (see inset, n = 11–13 animals in each group), Ovx induces
high LH levels in F2 (n = 8–13 per group) and BC (n = 8–12 per group) animals, irrespective
of their WG and TS. B, Corticosterone levels are not affected by Ovx in the same animal groups.
CTL, Control (non-Ovx animals).
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Fig. 3.
LHR expression in Ovx animals. A, Time course of LHR expression was screened up to 6
months after Ovx in parental strains and F1 and F2 progeny. RT-PCR shows LHR mRNA
expression in adrenal glands of all animal groups (bars are means of three to five samples per
group). No LHR mRNA could be detected in non-Ovx control adrenals. B,
Immunohistochemistry with a primary polyclonal anti-LHR antibody showing
immunoperoxidase staining in sections from Ovx-F1 and Ovx-C57BL/6J, 6 months after Ovx.
The tumorous region is evenly stained in Ovx-F1 within B cells (arrowheads) and A cells
(arrows) as shown in the two top panels. The top right panel shows a higher magnification of
the squared region as indicated in the top left panel.
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Fig. 4.
Inheritance of the obese phenotype. WG of Ovx C57BL/6J, DBA/2J, and their F1 crosses as
well as non-Ovx controls of the same groups (corresponding hatched bars of the same color)
was followed up to 6 months after Ovx (n = 10–46, see Materials and Methods for more details).
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Fig. 5.
Segregation of phenotypes. Penetrance of TS and WG was evaluated in F2 and BC animals.
Classification of adrenal gland histology with respect to tumor stage is described in Materials
and Methods. A, Percentages of F2 and BC mice with each stage of tumor development. B,
Distribution of WG in Ovx-F2 (n = 208) and BC (n = 125) animals as well as in their respective
non-Ovx controls (CTL; n = 19 –24) is shown. Each dot represents a single animal. C,
Correlation between WG and tumor stage in F2 and BC animals. Both groups exhibited similar
WG pattern with no effect according to tumor stage.
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Fig. 6.
Linkage analysis for WG and TS in Ovx-F2 animals. A and C, Genome scans in Ovx-F2 with
LOD scores (y-axis) for WG (A) and adrenal gland tumorigenesis (C). Chromosomes are
indicated on the x-axis, and LOD scores for each SNP are indicated with circles in the graph.
B and D, Peaks of linkage at the specified chromosome for WG (B) and tumorigenesis (D),
with the distance in centi-Morgans given along the x-axis, and the LOD scores given along the
y-axis. Horizontal thin lines indicate empirical P value thresholds estimated by 10,000
permutations.
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Fig. 7.
F2 two-dimensional genome-wide scan for TS. Epistasis for TS was estimated for each
chromosome, as represented along the x- and y-axes, with a two-locus model as described in
Materials and Methods. Above the diagonal are the LOD scores due to the interaction between
two QTLs (epistasis), and below the diagonal are the LOD scores due to the joint effects of
the QTLs. The color scale is representing the epistasis (left) and the joint LOD scores (right).
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Fig. 8.
Sfrp1 expression in adrenal gland tumors. A, Sfrp1 mRNA expression in adrenal glands was
assessed by RT-PCR from whole normal (n = 5) and tumorigenic (n = 10) adrenal glands (left
bars) as well from microdissected tumor areas (n = 4) and adjacent normal cortex (n = 4) (right
bars). Clear expression was observed in normal and tumor tissues, but the levels did not differ
significantly. B, Immunohistochemistry with a primary antibody against Sfrp1 was performed
on sections from tumorigenic adrenal glands: a, tumorigenic region, delimited by a black
line, showing less intense staining (blue area) of Sfrp1 compared with immunoreactivity of
the adjacent normal cortex (brown staining); b and c, distinct staining could be seen between
A cells (arrows; no staining) and B cells (arrowheads; staining); d, enlargement of the boxed
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region in c; e, early stage of tumorigenesis (3 months after Ovx) with clear lack of Sfrp1
expression in invading cells; f, normal cortex of an Ovx-C57BL/6J mouse with uniform
staining.
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